富祥药业: 重大信息内部报告制度

Core Viewpoint - The document outlines the internal reporting system for significant information at Jiangxi Fuxiang Pharmaceutical Co., Ltd, aiming to ensure timely, accurate, and complete disclosure of information to protect investors' rights [1][2]. Group 1: Internal Reporting System - The internal reporting system is designed to manage significant information that may impact the company's stock and derivatives trading prices [1][2]. - The system applies to the company, wholly-owned subsidiaries, controlling subsidiaries, and affiliated companies [1]. Group 2: Reporting Obligations - Internal information reporters include company directors, senior management, department heads, shareholders holding more than 5% of shares, and other relevant personnel [1][2]. - The board of directors is responsible for managing significant information and its disclosure [2]. Group 3: Definition of Significant Information - Significant information includes matters submitted for board or audit committee review, major transactions exceeding 10% of audited annual revenue or net profit, and significant litigation or arbitration matters exceeding 10 million RMB [3][4]. - Other categories of significant information include major changes in operations, environmental issues, and risks related to major shareholders or actual controllers [5][6]. Group 4: Reporting Procedures - Departments must report potential significant information to the board secretary immediately upon awareness [8][9]. - The reporting process includes timely updates on the progress of significant matters and any changes that may affect stock prices [9][10]. Group 5: Management and Responsibility - The company implements a real-time reporting system for significant information, ensuring that all relevant parties report accurately and promptly [18][19]. - The securities affairs department and board secretary are responsible for preparing and disclosing periodic reports, including annual and quarterly reports [19][20].